Ratings Jeisys Medical Inc.

Equities

A287410

KR7287410005

End-of-day quote Korea S.E. Other stock markets 18:00:00 2024-05-02 EDT			5-day change	1st Jan Change
10,450 ^KRW	-0.48%		+10.58%	-0.38%

04-11	AVAVA Announces Exclusive Distribution Partnership with Jeisys Medical Inc. for Korea and Japan	CI
04-04	AVAVA, Inc. announced that it expects to receive $14.999999 million in funding from Jeisys Medical Inc.	CI

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

Strengths

According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
The earnings growth currently anticipated by analysts for the coming years is particularly strong.
Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
Thanks to a sound financial situation, the firm has significant leeway for investment.
Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
Analysts covering this company mostly recommend stock overweighting or purchase.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
The opinion of analysts covering the stock has improved over the past four months.

Weaknesses

With an enterprise value anticipated at 4307.56 times the sales for the current fiscal year, the company turns out to be overvalued.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Sector: Advanced Medical Equipment & Technology

	1st Jan change	Capi.	ESG Refinitiv
JEISYS MEDICAL INC.	-0.38%	582M	-
THERMO FISHER SCIENTIFIC	+7.84%	218B	B
DANAHER CORPORATION	+7.35%	184B	B-
INTUITIVE SURGICAL, INC.	+13.04%	135B	B-
BOSTON SCIENTIFIC CORPORATION	+26.03%	107B	A-
SIEMENS HEALTHINEERS AG	-1.33%	62.38B	A-
EDWARDS LIFESCIENCES CORPORATION	+11.80%	51.37B	B+
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	+4.81%	50.9B	B+
AGILENT TECHNOLOGIES, INC.	+0.30%	40.87B	A
GE HEALTHCARE TECHNOLOGIES INC.	+2.78%	36.28B	-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes